サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411695

糖尿病性腎症治療市場：治療タイプ別、エンドユーザー別-2024-2030年の世界予測

Diabetic Nephropathy Treatment Market by Treatment Type (End-stage Renal Disease (ESRD) Treatment, Medications, Pharmacological Treatment), End-User (Hospitals, Nephrology Clinics) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
糖尿病性腎症治療市場：治療タイプ別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病性腎症治療市場規模は2023年に22億6,000万米ドルと推定され、2024年には23億8,000万米ドルに達すると予測され、CAGR 5.46%で2030年には32億8,000万米ドルに達すると予測されます。

糖尿病性腎症治療の世界市場

主な市場の統計
基準年[2023］ 22億6,000万米ドル
予測年[2024］ 23億8,000万米ドル
予測年【2030年 32億8,000万米ドル
CAGR（%） 5.46%
糖尿病性腎症治療 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは糖尿病性腎症治療市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、糖尿病性腎症治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-糖尿病性腎症治療市場の市場規模および予測は？

2-糖尿病性腎症治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-糖尿病性腎症治療市場における技術動向と規制の枠組みは？

4-糖尿病性腎症治療市場における主要ベンダーの市場シェアは？

5-糖尿病性腎症治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 高齢者人口の増加に伴い、世界的に糖尿病有病率が上昇
      • 糖尿病とその合併症の負担に対処するための政府主導の取り組み
      • 糖尿病性腎症に対する患者中心のケアプランの重視が高まる
    • 抑制要因
      • 糖尿病性腎症の治療費は高額
    • 機会
      • より効果的な新しい糖尿病性腎症治療法のイントロダクション
      • 糖尿病性腎症治療に対する償還ポリシーとヘルスケアの改善
    • 課題
      • 糖尿病性腎症に関連する併存疾患とケアの複雑さ
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 糖尿病性腎症治療市場治療タイプ別

  • 末期腎疾患（ESRD）の治療
    • 腎臓透析
    • 移植
  • 薬
    • アンジオテンシン2受容体遮断薬（ARB）
    • アンジオテンシン変換酵素（ACE）阻害剤
    • コレステロール低下薬
    • メトホルミン
  • 薬物治療

第7章 糖尿病性腎症治療市場：エンドユーザー別

  • 病院
  • 腎臓内科クリニック

第8章 南北アメリカの糖尿病性腎症治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の糖尿病性腎症治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの糖尿病性腎症治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma Limited
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • ChemoCentryx, Inc.
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Endo International PLC
    • IQVIA Inc.
    • Johnson & Johnson Services, Inc.
    • Mallinckrodt Pharmaceuticals
    • Merck & Co., Inc.
    • Mesoblast Ltd
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Reata Pharmaceuticals, Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEPHROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DIABETIC NEPHROPATHY TREATMENT MARKET DYNAMICS
  • FIGURE 7. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEPHROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY KIDNEY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 12. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN 2 RECEPTOR BLOCKERS (ARBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY NEPHROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. DIABETIC NEPHROPATHY TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-2A0283E256D1

[198 Pages Report] The Diabetic Nephropathy Treatment Market size was estimated at USD 2.26 billion in 2023 and expected to reach USD 2.38 billion in 2024, at a CAGR 5.46% to reach USD 3.28 billion by 2030.

Global Diabetic Nephropathy Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.26 billion
Estimated Year [2024] USD 2.38 billion
Forecast Year [2030] USD 3.28 billion
CAGR (%) 5.46%
Diabetic Nephropathy Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Nephropathy Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Nephropathy Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Nephropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, ChemoCentryx, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International PLC, IQVIA Inc., Johnson & Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mesoblast Ltd, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Reata Pharmaceuticals, Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Diabetic Nephropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • End-stage Renal Disease (ESRD) Treatment
      • Kidney Dialysis
      • Transplant
    • Medications
      • Angiotensin 2 Receptor Blockers (ARBs)
      • Angiotensin-converting Enzyme (ACE) Inhibitors
      • Cholesterol-lowering Drugs
      • Metformin
    • Pharmacological Treatment
  • End-User
    • Hospitals
    • Nephrology Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Nephropathy Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Nephropathy Treatment Market?

3. What are the technology trends and regulatory frameworks in the Diabetic Nephropathy Treatment Market?

4. What is the market share of the leading vendors in the Diabetic Nephropathy Treatment Market?

5. Which modes and strategic moves are suitable for entering the Diabetic Nephropathy Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Diabetic Nephropathy Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
      • 5.1.1.2. Government-led initiatives to address the burden of diabetes and its complications
      • 5.1.1.3. Growing emphasis on patient-centric care plans for diabetic nephropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diabetic nephropathy treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and more effective diabetic nephropathy treatments
      • 5.1.3.2. Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Comorbidities and complexity of care associated with diabetic nephropathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Diabetic Nephropathy Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. End-stage Renal Disease (ESRD) Treatment
    • 6.3.1. Kidney Dialysis
    • 6.3.2. Transplant
  • 6.3. Medications
    • 6.4.1. Angiotensin 2 Receptor Blockers (ARBs)
    • 6.4.2. Angiotensin-converting Enzyme (ACE) Inhibitors
    • 6.4.3. Cholesterol-lowering Drugs
    • 6.4.4. Metformin
  • 6.4. Pharmacological Treatment

7. Diabetic Nephropathy Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Nephrology Clinics

8. Americas Diabetic Nephropathy Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Nephropathy Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Nephropathy Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. AbbVie Inc.
    • 12.1.3. Amgen Inc.
    • 12.1.4. AstraZeneca PLC
    • 12.1.5. Aurobindo Pharma Limited
    • 12.1.6. Bayer AG
    • 12.1.7. Boehringer Ingelheim International GmbH
    • 12.1.8. Bristol-Myers Squibb Company
    • 12.1.9. ChemoCentryx, Inc.
    • 12.1.10. Daiichi Sankyo Company, Limited
    • 12.1.11. Dr. Reddy's Laboratories Ltd.
    • 12.1.12. Eli Lilly and Company
    • 12.1.13. Endo International PLC
    • 12.1.14. IQVIA Inc.
    • 12.1.15. Johnson & Johnson Services, Inc.
    • 12.1.16. Mallinckrodt Pharmaceuticals
    • 12.1.17. Merck & Co., Inc.
    • 12.1.18. Mesoblast Ltd
    • 12.1.19. Novartis AG
    • 12.1.20. Otsuka Pharmaceutical Co., Ltd.
    • 12.1.21. Pfizer, Inc.
    • 12.1.22. Reata Pharmaceuticals, Inc.
    • 12.1.23. Sanofi SA
    • 12.1.24. Sun Pharmaceutical Industries Ltd.
    • 12.1.25. Teva Pharmaceutical Industries Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing